Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In formulating the response of the healthcare system to the COVID-19 pandemic, the true toll of the chronic consequences of SARS-CoV-2 infection must be uncovered and strategies must be devised for providing integrated care to those with long-term illness.
Scientists and health professionals must commit to preparing for the health effects of climate change through increased research, education and self-assessment.
Delivering the potential of artificial intelligence in clinical decision-making will require testing interventions in well-designed randomized clinical trials and reporting these results in a standardized and transparent fashion.
The rapid rollout of digital health approaches in the ongoing global COVID-19 pandemic has neglected to prioritize data privacy and is a missed opportunity for building users’ trust in these technologies for future outbreaks and quotidian healthcare.
Government officials who disseminate unsupported claims about the novel coronavirus undermine public trust in science and in the public-health efforts that are essential to bringing the COVID-19 pandemic under control.
A surge in mental-health problems related to the COVID-19 pandemic is on the horizon. The time to prepare and prevent another health-crisis wave is now.
As the COVID-19 pandemic shuts down labs across the globe, funders and institutions must step up to support scientists and ensure the healthy future of research.
Secondary use of patient health data can be a boon for medical research and development, but only if researchers can cultivate patient trust in the system.
As the outbreak of a deadly new coronavirus in China and its rapid spread is rattling countries, only the collective international experience and advances derived from past outbreaks can accelerate its control.
Large-scale multi-modal information on patients’ health is ever increasing, providing an opportunity to use big data for taking individualized medicine to a global scale.
The recent report of an antisense oligonucleotide therapy designed for only one patient spotlights regulatory, economic and ethical issues that must be grappled with in an era of accelerated development of ‘ultra-personalized’ drugs.
The rise in cardiometabolic diseases is linked to the availability of unhealthy products from industry, such as ultraprocessed foods, and studying the efficacy of intervention strategies against these products must be high on the research agenda.
Nature Medicine is taking a comprehensive approach for reporting clinical studies with the aim to increase transparency, promote rigorous reporting standards and engage with the community to meet the challenges of contemporary medicine.
As the clinical potential of RNA therapeutics begins to be unveiled, expanding the range of tissue types that can be targeted for delivery of these drugs is now the main hurdle to overcome.
‘Precision’ in a health context is usually thought to apply to the individual and seems conceptually at odds with efforts in public health directed toward improving population-level health metrics. But are these two aims truly irreconcilable?
Recent measles outbreaks worldwide highlight the urgency of tracking and countering vaccine hesitancy to ensure the continued success of immunization programs.
The National Institutes of Health Human Microbiome Project is coming to a close, offering an opportunity to reflect on its legacy and the urgent need to understand the microbiome of underrepresented populations.
Immune interventions capable of preventing or eradicating HIV infection have yet to achieve broad success in humans. Renewed vigor in the clinical trial arena may bring us closer to that goal.
